Loading…

MiniMed Group, Inc.MMEDCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Diabetes device maker (insulin pumps, sensors) spun off from Medtronic in 2026, continuing the legacy MiniMed diabetes business.

Momentum strong 74
Mkt cap
$4.78B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$129M
20-day average traded
Fwd P/E
26.3×
forward earnings
ROIC−WACC
+3.3 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
42 days
30 Dec 2026
Close · USD$16.99
1D-4.4%
1W-6.9%
1M-2.9%
3M-15.8%
6M+46.1%
YTDn/a
1Yn/a
ATR %5.8%
52w lowhigh30.4% off high

What MiniMed does

Diabetes device maker (insulin pumps, sensors) spun off from Medtronic in 2026, continuing the legacy MiniMed diabetes business.

Sells insulin pump systems and the consumables patients must reorder, such as infusion sets and sensors, so each pump placed brings repeat income for years of use; insurers pay for most of it. It operates standalone after separating from Medtronic.

Products and services

  • MiniMed insulin pump systems
  • CGM ecosystem integration
  • Diabetes management software/apps

Customers

  • People with Type 1 diabetes
  • Endocrinologists

Where it sits in the supply chain

  • Healthcare
  • Medical devices
  • Insulin pump and diabetes management…

What could go right

  • Standalone strategic focus after Medtronic separation
  • Automated insulin delivery adoption growth

What could go wrong

  • Execution risk as a newly standalone company
  • Competitive share loss to Omnipod's tubeless design

Moat: narrow (installed base, switching costs, brand). Long-standing MiniMed brand and installed pump base, though newly independent after decades inside Medtronic.

Headquarters: Northridge, California, USA · Founded: 1983 · Employees: 8,000

Named competitors

MiniMed at a glance

Size MiniMed (MMED) is a United States Health Care company (Medical Specialties) with a market value of $4.78B, the 1208th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.99 on 18 Nov 2026.

Performance Over six months the shares gained 46.1%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 14.2% over the last twelve months (peer median +7.0%); the operating margin is 13.9% (peer median 13.6%).

Valuation It trades at 26.3× forward earnings against a peer median of 20.4× (5th most expensive of 20).

Capital Return on invested capital runs 3.3 points above its cost of capital (6.6% WACC).

Backlog Backlog (remaining performance obligations) was $23.0M at 23 Jan 2026. Backlog detail →

Short interest Short interest is 3.5% of the free float (30 Oct 2026).

Next results Next results expected around 30 Dec 2026 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026MMED 145Peer median 126
Six months, rebased to 100: MiniMed against the median of its 20 peers (local-currency closes).

MiniMed financials

Reported figures in USD; fiscal year ends 2026-04-30. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$3.10B$2.71B
Revenue growth—+14%—
Gross profitn/a$1.80B$1.56B
EBITDAn/a$587M$486M
Net incomen/a-$333M-$213M
Free cash flown/a-$420M-$53.0M
Capital expendituren/a$223M$193M
Total debt$59.0M$53.0M$67.0M

Quarterly statements and history in the cockpit →

MiniMed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%DIA300677SHCGRALICUIMMSILIVNSTVN002223HAEFIECDNA002432NVST6886171SXP603014TECN4203AMBU-BMMED6-month return →1-month return →
Up and to the right = strong over both horizons. MiniMed is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×DIA300677SHCICUIMMSILIVNSTVNHAEFIECDNA002432NVST6886171SXP603014TECN4203AMBU-BMMEDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MiniMed is the large dot.

MiniMed competitors and peer comparison

Head to head with its named competitors (MMED vs PODD vs TNDM vs DXCM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
MiniMed MMED$4.78B+46%+14%14%26.3×n/a
Insulet PODD$9.71B-11%+26%18%18.6×10.6%
Tandem Diabetes Care TNDM$1.19B+13%+7%-2%n/an/a
Dexcom DXCM$30.8B+16%+13%24%28.0×19.6%

How MiniMed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MiniMed against its 20 peers (data as of 18 Nov 2026)
MeasureMMEDPeer medianRank in peer set
1-month return-2.9%+5.5%8th lowest of 21
6-month return+46.1%+23.4%5th highest of 21
Distance from 52-week high-30.4%-16.4%5th lowest of 21
Revenue growth (TTM)+14.2%+7.0%6th highest of 21
Operating margin13.9%13.6%10th highest of 20
Forward P/E26.3×20.4×5th most expensive of 20
ROIC minus cost of capital+3.3 pp+2.0 pp8th highest of 20
EV / EBITDA7.9×13.8×3rd cheapest of 14
Net debt / EBITDA-0.2×0.9×4th least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%

MiniMed backlog

MiniMed reported $23.0M of remaining performance obligations at 23 Jan 2026.

Questions

Who are MiniMed's main competitors?
Named competitors: Insulet Corporation (PODD), Tandem Diabetes Care (TNDM), Dexcom (DXCM). The cockpit's measured peer set (industry) also includes DiaSorin (DIA.MI), Intco Medical Technology (300677.SZ), Sotera Health (SHC), GRAIL (GRAL), ICU Medical (ICUI), Merit Medical Systems (MMSI).
Is MiniMed expensive compared with its peers?
On forward p/e it trades at 26.3× against a peer median of 20.4×, 5th most expensive of 20 in its peer set.
How has MiniMed stock performed?
Over six months to 18 Nov 2026 the shares returned +46.1% against +23.4% for the median peer.
What is MiniMed's backlog?
MiniMed's remaining performance obligations (contracted revenue not yet recognised) were $23.0M at 23 Jan 2026.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.